Business Medical Dialogues
    • facebook
    • twitter
    Sign in Signup
    • facebook
    • twitter
    Sign in Signup
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    Sign InRegister
    Business Medical Dialogues
    Sign inRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Asbestos scare: CDSCO...

    Asbestos scare: CDSCO draws samples of J&J baby powder from HP plant

    Medical Dialogues BureauBy Medical Dialogues BureauPublished On 2018-12-20T17:12:30+05:30  |  Updated On 2021-08-17T12:20:26+05:30

    The CDSCO, under the Union Health Ministry, said over the next four to five days, drug inspectors will search manufacturing plants and wholesalers of J&J's talcum powder and collect samples of the powder for testing.


    New Delhi: The country's top drug regulator, the CDSCO, drew samples of Johnson and Johnson's baby powder from the company's Baddi plant in Himachal Pradesh on Wednesday amid reports that the product allegedly contained cancer-causing asbestos. This was part of a massive nationwide action against the American multinational pharmaceutical major to draw samples of their talcum powder.


    The company said they were "fully cooperating" with the Central Drugs Standard Control Organization (CDSCO) by providing tests and samples, and asserted that the characterisation of these visits as 'raids or seizures is "incorrect".


    The CDSCO, under the Union Health Ministry, said over the next four to five days, drug inspectors will search manufacturing plants and wholesalers of J&J's talcum powder and collect samples of the powder for testing.


    The inspectors will check if the products complied with the cosmetics standards in India, officials said.


    "The action will take place at 12-15 locations across the country and samples of all brands of the Johnson and Johnson talcum powder will be collected for testing to check for the presence of asbestos.


    "Samples of raw material, as well as the finished product from retail stores, are being collected," a government official said.


    Sources said the CDSCO has constituted a team of 100 drug inspectors for the purpose.


    The country's top drug regulator will test the collected samples for the presence of asbestos and also check if the brands complied with all regulatory and manufacturing standards, the official said.


    The effects of long-term unsafe asbestos exposure on human health are well documented and asbestos fibres are easily inhaled and carried into the lower regions of the lung where those can cause fibrotic lung disease (asbestosis) and changes in the lining of the chest cavity (pleura).


    These diseases can lead to reduced respiratory function and death, while long-term inhalation of asbestos fibres also increases the risk of lung cancer and mesothelioma.


    According to a senior official, powder samples of Johnson and Johnson were tested in 2016 but they were found to be complying with Indian standards.


    Some recent reports claimed that the firm allegedly knew for decades about the presence of cancer-causing asbestos in their product.


    The action by CDSCO came at a time the American pharmaceutical major is already embroiled in a controversy over its faulty hip implants.


    The Union Health Ministry recently approved the formula for determination of compensation for patients who prior to August 2010, had received faulty articular surface replacement hip implants manufactured by Johnson and Johnson.


    When contacted, the company confirmed that a few of its facilities were visited by the CDSCO and local Food and Drug Administration officials on Wednesday.


    A company spokesperson said they are "fully cooperating" with the authorities by providing tests and samples.


    "The characterization of these visits as 'raids or seizures' is incorrect as has been reported in some instances. The tests have been conducted in the regular way that the FDA collects samples," the spokesperson said.


    The company said Johnson & Johnson's baby powder is asbestos-free and doesn't cause cancer.


    "We have scientific evidence to prove that our talcum powder is safe and beneficial for use," the spokesperson said.


    The company said the safety of cosmetic talc is based on a long history of safe use and decades of research and clinical evidence by independent researchers and scientific review boards across the world.


    It pointed out that in the past, authorities in India like the FDA's and the CDSCO have confirmed that its products comply with Indian standards and are free of asbestos.


    "We unequivocally stand by the safety of our products, are fully compliant with regulatory standards and requirements in India and will continue to work with the regulatory authorities," the spokesperson said.


    According to reports, earlier this year, a Missouri jury in the US ordered the company to pay a record USD 4.69 billion to 22 women who alleged that its talc-based products, including its baby powder, contained asbestos and caused them to develop ovarian cancer.


    Also Read: CDSCO seizes illegal cosmetics, serum worth Rs 4 crore

    asbestos fibres Asbestos scare CDSCO Central Drugs Standard Control Organization FDA J&J Johnson and Johnson lung cancer mesothelioma ovarian cancer Union Health Ministry 
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society petition

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society...

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Pharmaceuticals safe in PET packaging: High-level committee

      Pharmaceuticals safe in PET packaging: High-level committee

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Top priority on Delivery of Medicines through Speed Post: Minister

      Top priority on Delivery of Medicines through Speed Post: Minister

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 29 March 2022 11:15 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X